Clinical uncertainty for the use of rivaroxaban in obesity
- 2 March 2021
- journal article
- letter
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 19 (3), 870-871
- https://doi.org/10.1111/jth.15200
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysisJournal of Thrombosis and Haemostasis, 2020
- Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous ThromboembolismPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2020
- Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective studyResearch and Practice in Thrombosis and Haemostasis, 2018
- Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial)The American Journal of Cardiology, 2017
- Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTHJournal of Thrombosis and Haemostasis, 2016
- Treatment of venous thromboembolism with rivaroxaban in relation to body weightThrombosis and Haemostasis, 2016
- ErrataThe Journal of Clinical Pharmacology, 2008
- Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy SubjectsThe Journal of Clinical Pharmacology, 2007